Cargando…

Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93: Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients

Detalles Bibliográficos
Autores principales: Wambier, Carlos G., Nau, Gerard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Association of Urology. Published by Elsevier B.V. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864079/
https://www.ncbi.nlm.nih.gov/pubmed/35304000
http://dx.doi.org/10.1016/j.eururo.2022.01.049
_version_ 1784655374449639424
author Wambier, Carlos G.
Nau, Gerard J.
author_facet Wambier, Carlos G.
Nau, Gerard J.
author_sort Wambier, Carlos G.
collection PubMed
description
format Online
Article
Text
id pubmed-8864079
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Association of Urology. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-88640792022-02-23 Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93: Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients Wambier, Carlos G. Nau, Gerard J. Eur Urol Letter to the Editor European Association of Urology. Published by Elsevier B.V. 2022-06 2022-02-23 /pmc/articles/PMC8864079/ /pubmed/35304000 http://dx.doi.org/10.1016/j.eururo.2022.01.049 Text en © 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Wambier, Carlos G.
Nau, Gerard J.
Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93: Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients
title Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93: Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients
title_full Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93: Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients
title_fullStr Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93: Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients
title_full_unstemmed Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93: Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients
title_short Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93: Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients
title_sort re: karin welén, ebba rosendal, magnus gisslén, et al. a phase 2 trial of the effect of antiandrogen therapy on covid-19 outcome: no evidence of benefit, supported by epidemiology and in vitro data. eur urol. 2022;81:285–93: positive effects of enzalutamide for hospitalized covid-19 patients
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864079/
https://www.ncbi.nlm.nih.gov/pubmed/35304000
http://dx.doi.org/10.1016/j.eururo.2022.01.049
work_keys_str_mv AT wambiercarlosg rekarinwelenebbarosendalmagnusgisslenetalaphase2trialoftheeffectofantiandrogentherapyoncovid19outcomenoevidenceofbenefitsupportedbyepidemiologyandinvitrodataeururol20228128593positiveeffectsofenzalutamideforhospitalizedcovid19patients
AT naugerardj rekarinwelenebbarosendalmagnusgisslenetalaphase2trialoftheeffectofantiandrogentherapyoncovid19outcomenoevidenceofbenefitsupportedbyepidemiologyandinvitrodataeururol20228128593positiveeffectsofenzalutamideforhospitalizedcovid19patients